{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:30:35Z","timestamp":1781854235531,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cllc.2024.01.002","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T18:34:43Z","timestamp":1705602883000},"page":"319-328.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["HER2-Mutant Advanced and\/or Metastatic Non\u2013Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes"],"prefix":"10.1016","volume":"25","author":[{"given":"Sarah","family":"Waliany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Engel-Nitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2024.01.002_bib0001","unstructured":"American Cancer Society. Cancer facts & figures 2022. Available at: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2022.html Accessed: September 16, 2022."},{"issue":"12","key":"10.1016\/j.cllc.2024.01.002_bib0002","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2024.01.002_bib0003","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.lungcan.2007.03.012","article-title":"National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care","volume":"57","author":"Little","year":"2007","journal-title":"Lung Cancer."},{"issue":"4","key":"10.1016\/j.cllc.2024.01.002_bib0004","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jjco\/hyu003","article-title":"Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project","volume":"44","author":"Matsuda","year":"2014","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2024.01.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100260","article-title":"Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations","volume":"6","author":"Riudavets","year":"2021","journal-title":"ESMO Open."},{"issue":"1","key":"10.1016\/j.cllc.2024.01.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100395","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open."},{"issue":"2","key":"10.1016\/j.cllc.2024.01.002_bib0007","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdv573","article-title":"Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort","volume":"27","author":"Mazieres","year":"2016","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.cllc.2024.01.002_bib0008","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.cllc.2024.01.002_bib0009","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1200\/JCO.2017.35.15_suppl.8509","article-title":"Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC)","volume":"35","author":"Stinchcombe","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.01.002_bib0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-18-1590","article-title":"Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers","volume":"25","author":"Peters","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cllc.2024.01.002_bib0011","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","article-title":"A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer","volume":"13","author":"Hotta","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.01.002_bib0012","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer. , 2022. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung Accessed: September 16, 2022."},{"issue":"suppl 7","key":"10.1016\/j.cllc.2024.01.002_bib0013","first-page":"S808","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer: interim results from the phase 2 DESTINY-Lung02 trial","volume":"33","author":"Goto","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2024.01.002_bib0014","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2024.01.002_bib0015","unstructured":"Daiichi-Sankyo. ENHERTU approved in the U.S>as the first HER2 directed therapy for patients with previously treated HER2 mutant metastatic non-small cell lung cancer. Press Release. Available at: https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202208\/20220811_E2.pdf. Accessed: April 20, 2023, 2023."},{"issue":"5","key":"10.1016\/j.cllc.2024.01.002_bib0016","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non\u2013small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.cllc.2024.01.002_bib0017","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.21.01113","article-title":"Poziotinib for patients with HER2 exon 20 mutant non-small-cell lung cancer: results from a phase II trial","volume":"40","author":"Elamin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2024.01.002_bib0018","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial","volume":"40","author":"Le","year":"2022","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.cllc.2024.01.002_bib0019","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.20.00297","article-title":"Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II study","volume":"38","author":"Zhou","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2024.01.002_bib0020","article-title":"Real world characteristics and clinical outcomes of HER2-mutant non-small cell lung cancer patients detected by next-generation sequencing","author":"Ahn","year":"2022","journal-title":"Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.cllc.2024.01.002_bib0021","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.cllc.2022.05.015","article-title":"Characterization of ERBB2 (HER2) alterations in metastatic non-small cell lung cancer and comparison of outcomes of different trastuzumab-based regimens","volume":"23","author":"Waliany","year":"2022","journal-title":"Clin Lung Cancer."},{"key":"10.1016\/j.cllc.2024.01.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920936090","article-title":"Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies","volume":"12","author":"Zhou","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2024.01.002_bib0023","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1759-7714.13317","article-title":"Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China","volume":"11","author":"Xu","year":"2020","journal-title":"Thorac Cancer."},{"issue":"1","key":"10.1016\/j.cllc.2024.01.002_bib0024","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12885-018-4277-x","article-title":"Outcomes of pemetrexed-based chemotherapies in HER2-mutant lung cancers","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer."},{"issue":"21","key":"10.1016\/j.cllc.2024.01.002_bib0025","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/cncr.30869","article-title":"HER2 mutations in lung adenocarcinomas: a report from the lung cancer mutation consortium","volume":"123","author":"Pillai","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.cllc.2024.01.002_bib0026","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/gcc.22442","article-title":"Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas","volume":"56","author":"Gow","year":"2017","journal-title":"Genes Chromosomes Cancer."},{"key":"10.1016\/j.cllc.2024.01.002_bib0027","unstructured":"Optum. Ignite insights with Optum EHR data. 2024. Available at: https:\/\/www.optum.com\/content\/dam\/optum3\/optum\/en\/resources\/sell-sheet\/ehr-data-sell-sheet.pdf. Accessed: January 3, 2024."},{"key":"10.1016\/j.cllc.2024.01.002_bib0028","unstructured":"Optum. Optum EHR Data. 2024. Available at: https:\/\/www.optum.com\/business\/life-sciences\/real-world-data\/ehr-data.html. Accessed: January 3, 2024."},{"issue":"6","key":"10.1016\/j.cllc.2024.01.002_bib0029","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cllc.2024.01.002_bib0030","unstructured":"ECOG-ACRIN Cancer Research Group. ECOG Performance Status Scale. , 2022. Available at: https:\/\/ecog-acrin.org\/resources\/ecog-performance-status\/ Accessed: November 17, 2022."},{"issue":"7","key":"10.1016\/j.cllc.2024.01.002_bib0031","doi-asserted-by":"crossref","first-page":"807","DOI":"10.6004\/jnccn.2018.0062","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 5.2018","volume":"16","author":"Ettinger","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.cllc.2024.01.002_bib0032","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jtho.2016.11.2221","article-title":"Increasing rates of no treatment in advanced-stage non-small cell lung cancer patients: a propensity-matched analysis","volume":"12","author":"David","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2024.01.002_bib0033","article-title":"Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer","volume":"6","author":"Sadik","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2024.01.002_bib0034","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2022.03.004","article-title":"Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network","volume":"166","author":"Robert","year":"2022","journal-title":"Lung Cancer."}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T20:29:54Z","timestamp":1728937794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1525730424000044"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.01.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2-Mutant Advanced and\/or Metastatic Non\u2013Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}